BioLineRx Receives Approval To Complete Phase 1/2 Clinical Trials Of BL-1040, A Breakthrough Treatment For Acute Myocardial Infarction

BioLineRx Ltd. (TASE:BLRX), a clinical stage drug development company, announced that the Independent Safety Monitoring Board (ISMB) for the BL-1040 pilot study authorized the completion of the Phase 1/2 study and enrollment of the additional 25 patients. The ISMB’s decision is based on safety assessments of the first 5 patients to complete at least 30 days of follow up following treatment with BL-1040 without noticeable adverse events.

More: continued here

Filed under: Cardiovascular on January 14th, 2009